The use of the prostate-specific antigen (psa) test and a digital rectal examination (dre) to screen for prostate cancer—and whether such use can reduce prostate cancer–specific mortality—has universally been regarded as controversial despite the publication of more than 1000 articles in the medical and scientific literature. The gene discussed is KLK3; the disease is Familial prostate cancer.